Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
2 Top Growth Stocks to Buy With $500
10:07am, Thursday, 14'th Sep 2023
Sarepta Therapeutics is successfully developing treatments for a rare and devastating disease. Shopify's recent moves should make it even stronger in the fast-growing e-commerce industry.
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
08:30am, Tuesday, 05'th Sep 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
01:00pm, Wednesday, 23'rd Aug 2023
Wall Street is expecting big things from the rare disease specialist Sarepta Therapeutics in 2023 and beyond. However, the company does face some important challenges that could stunt its growth.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
10:00am, Tuesday, 22'nd Aug 2023
CRISPR Therapeutics is using a novel technique to develop innovative therapies. Sarepta Therapeutics is developing medicines targeting a difficult-to-treat disease.
Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript
09:57pm, Wednesday, 02'nd Aug 2023
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Director Doug Ingram - President and CEO Louise Rodino-Kl
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates
07:28pm, Wednesday, 02'nd Aug 2023
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to loss of $2.65 per share a year ago.
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:39am, Tuesday, 25'th Jul 2023
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics: 'Hold' Amid Market Myopia
05:49am, Thursday, 13'th Jul 2023
Sarepta reported a $516.8M loss in Q1 2023 but saw increased revenues ($253.5M) and holds $1.9B in assets. FDA's narrower approval for Elevidys impacted the stock but could expand with a successful co
3 Biotech Stocks to Sell Before They Damage Your Portfolio
05:33pm, Wednesday, 12'th Jul 2023
There are several reasons that investors should be cautious about buying or holding biotech stocks at this point. First, the Street is generally bearish on the sector lately.
Sarepta (SRPT) Sells Priority Review Voucher for $102M
11:35am, Thursday, 06'th Jul 2023
Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.
Sarepta Therapeutics completes sale of priority review voucher for $102 million
08:37am, Wednesday, 05'th Jul 2023
Sarepta Therapeutics Inc. SRPT, -0.90% said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $102 million and will use the proceeds for R&D. Sarepta was aw
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
08:30am, Monday, 03'rd Jul 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%?
08:45am, Friday, 30'th Jun 2023
Sarepta recently secured conditional approval for its gene-editing therapy. But the therapy's high price tag might slow down its uptake among patients.
Sarepta CEO Doug Ingram: We should be profitable by the end of next year if we achieve our goals
12:21pm, Thursday, 29'th Jun 2023
Doug Ingram, Sarepta Therapeutics CEO, joins 'Squawk on the Street' to discuss the FDA's concerns with Sarepta's latest approval, how confident Ingram is the company's latest drug approval won't get r
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)
09:01am, Tuesday, 27'th Jun 2023
On May 15, Sarepta Therapeutics Inc. NASDAQ: SRPT learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA) advisors. Natu
